Friday 7th June, 2013
1:00pm to 1:30pm
Cloud computing has finally arrived in the pharmaceutical industry and while many companies are still slow to adopt, we expect that resistance to decrease substantially in the next few years as decision makers learn more about security on the cloud and ultimately are influenced by their many colleagues who have already made the move to the cloud. One of the main advantages in moving to the cloud is now you only have to pay for hardware resources as you need them; however, as a result, this means that there is now a real cost associated with the time it takes to run calculations on the cloud. Software speed has always been touted as one of OpenEye's core benefits, but now in a world where you may need to pay for every compute cycle, getting the same or better answers faster takes on a whole new meaning.
Sign in to add slides, notes or videos to this session